Maternally Administered Sustained-Release Naltrexone in Rats Affects Offspring Neurochemistry and Behaviour in Adulthood

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Farid, Waleed O ^a   Lawrence, Andrew J ^c   Krstew, Elena V ^c   Tait, Robert J ^a,d   Hulse, Gary K ^a   Dunlop, Sarah A ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MORPHINE; NALTREXONE; PLACEBO; PREPROENKEPHALIN;

ABSTINENCE; ADOLESCENT; ADULT ANIMAL; ADULTHOOD; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BIRTH; BIRTH WEIGHT; BRAIN; CONCEPTION; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; DRUG SEEKING BEHAVIOR; FEMALE; GENE EXPRESSION; LITTER SIZE; LOCOMOTION; MORPHOMETRICS; NEUROCHEMISTRY; NEWBORN; NONHUMAN; PREGNANCY; PRENATAL DRUG EXPOSURE; PROGENY; RAT; SUSTAINED DRUG RELEASE; WEANING;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DELAYED-ACTION PREPARATIONS; DYNORPHINS; ENKEPHALINS; FEMALE; GENE EXPRESSION; MALE; MORPHINE; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NEOSTRIATUM; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; SELF ADMINISTRATION;

RATTUS;

EID: 84871562298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052812     Document Type: Article

References (112)

1. Kirchmayer U, Davoli M, Verster AD, Amato L, Ferri A, et al. (2002) A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 97: 1241-1249.
2. Johansson BA, Berglund M, Lindgren A, (2006) Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 101: 491-503.
3. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, et al. (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293: 1617-1625.
4. Kranzler HR, Wesson DR, Billot L, (2004) Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 28: 1051-1059.
5. Caswell A (2005) MIMS Bi-Monthly. Sydney: CMPMedica Australia.
6. Hulse GK, O'Neil G, Pereira C, Brewer C, (2001) Obstetric and neonatal outcomes associated with maternal naltrexone exposure. Aust N Z J Obstet Gynaecol 41: 424-428.
7. Hulse GK, Arnold-Reed DE, O'Neil G, Hansson RC, (2003) Naltrexone implant and blood naltrexone levels over pregnancy. Aust N Z J Obstet Gynaecol 43: 386-388.
8. Hulse GK, O'Neil G, (2002) A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user. Aust N Z J Obstet Gynaecol 42: 104-105.
9. Hulse GK, O'Neil G, Arnold-Reed DE, (2004) Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. Int J Gynaecol Obstet 85: 170-171.
10. Ngo HT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK, (2008) Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry 32: 23-28.
11. McLaughlin PJ, Tobias SW, Lang CM, Zagon IS, (1997) Chronic exposure to the opioid antagonist naltrexone during pregnancy: maternal and offspring effects. Physiol Behav 62: 501-508.
12. McLaughlin PJ, Tobias SW, Lang CM, Zagon IS, (1997) Opioid receptor blockade during prenatal life modifies postnatal behavioral development. Pharmacol Biochem Behav 58: 1075-1082.
13. Zagon IS, McLaughlin PJ, (1986) Opioid antagonist (naltrexone) modulation of cerebellar development: histological and morphometric studies. J Neurosci 6: 1424-1432.
14. Zagon IS, Wu Y, McLaughlin PJ, (1999) Opioid growth factor and organ development in rat and human embryos. Brain Res 839: 313-322.
15. de Cabo de la Vega C, Pujol A, Paz Viveros M, (1995) Neonatally administered naltrexone affects several behavioral responses in adult rats of both genders. Pharmacol Biochem Behav 50: 277-286.
16. Harry GJ, Rosecrans JA, (1979) Behavioral effects of perinatal naltrexone exposure: a preliminary investigation. Pharmacol Biochem Behav 11Suppl: 19-22.
17. Zagon IS, McLaughlin PJ, (1985) Naltrexone's influence on neurobehavioral development. Pharmacol Biochem Behav 22: 441-448.
18. Zagon IS, Tobias SW, Hytrek SD, McLaughlin PJ, (1998) Opioid receptor blockade throughout prenatal life confers long-term insensitivity to morphine and alters mu opioid receptors. Pharmacol Biochem Behav 59: 201-207.
19. Robinson TE, Berridge KC, (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18: 247-291.
20. Robinson TE, Browman KE, Crombag HS, Badiani A, (1998) Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neurosci Biobehav Rev 22: 347-354.
21. Georges F, Stinus L, Bloch B, Le Moine C, (1999) Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. Eur J Neurosci 11: 481-490.
22. Mansour A, Fox CA, Akil H, Watson SJ, (1995) Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18: 22-29.
23. Steiner H, Gerfen CR, (1998) Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 123: 60-76.
24. Liu Y, Sunderland VB, O'Neil AG, (2006) In vitro and in vivo release of naltrexone from biodegradable depot systems. Drug Dev Ind Pharm 32: 85-94.
25. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, et al. (2004) Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 9: 59-65.
26. Frank P, Schoenhard GL, Burton E, (1991) A method for rapid and frequent blood collection from the rat tail vein. J Pharmacol Methods 26: 233-238.
27. Bugge CJL, Grun I, Stanfor K, Tan MS, Garcia DB (1996) Determination of Naltrexone and 6-b-Naltrexol in human plasma by LC-MS-MS. Austin, TX: CEDRA Corporation.
28. DiResta GR, Lee JB, Arbit E, (1991) Measurement of brain tissue specific gravity using pycnometry. J Neurosci Methods 39: 245-251.
29. Huang WL, Beazley LD, Quinlivan JA, Evans SF, Newnham JP, et al. (1999) Effect of corticosteroids on brain growth in fetal sheep. Obstet Gynecol 94: 213-218.
30. Owoeye O, Farombi EO, Onwuka SK, (2011) Gross morphometric reduction of rats' cerebellum by gamma irradiation was mitigated by pretreatment with Vernonia amygdalina leaf extract. Rom J Morphol Embryol 52: 81-88.
31. McPherson CS, Lawrence AJ, (2006) Exposure to amphetamine in rats during periadolescence establishes behavioural and extrastriatal neural sensitization in adulthood. Int J Neuropsychopharmacol 9: 377-392.
32. Brown RM, Short JL, Cowen MS, Ledent C, Lawrence AJ, (2009) A differential role for the adenosine A2A receptor in opiate reinforcement vs opiate-seeking behavior. Neuropsychopharmacology 34: 844-856.
33. Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates. Amsterdam: Elsevier Academic Press.
34. Cowen MS, Rezvani AH, Jarrott B, Lawrence AJ, (1999) Ethanol consumption by Fawn-Hooded rats following abstinence: effect of naltrexone and changes in mu-opioid receptor density. Alcohol Clin Exp Res 23: 1008-1014.
35. Djouma E, Lawrence AJ, (2002) The effect of chronic ethanol consumption and withdrawal on mu-opioid and dopamine D(1) and D(2) receptor density in Fawn-Hooded rat brain. J Pharmacol Exp Ther 302: 551-559.
36. Cowen MS, Lawrence AJ, (2001) Alterations in central preproenkephalin mRNA expression after chronic free-choice ethanol consumption by fawn-hooded rats. Alcohol Clin Exp Res 25: 1126-1133.
37. Carroll ME, Campbell UC, Heideman P, (2001) Ketoconazole suppresses food restriction-induced increases in heroin self-administration in rats: sex differences. Exp Clin Psychopharmacol 9: 307-316.
38. Carroll ME, France CP, Meisch RA, (1979) Food deprivation increases oral and intravenous drug intake in rats. Science 205: 319-321.
39. Carroll ME, Meisch RA, (1981) Determinants of increased drug self-administration due to food deprivation. Psychopharmacology (Berl) 74: 197-200.
40. Lang WJ, Latiff AA, McQueen A, Singer G, (1977) Self administration of nicotine with and without a food delivery schedule. Pharmacol Biochem Behav 7: 65-70.
41. Singer G, Simpson F, Lang WJ, (1978) Schedule induced self injections of nicotine with recovered body weight. Pharmacol Biochem Behav 9: 387-389.
42. Grasing K, Li N, He S, Parrish C, Delich J, et al. (2003) A new progressive ratio schedule for support of morphine self-administration in opiate dependent rats. Psychopharmacology (Berl) 168: 387-396.
43. Roberts DCS, Richardson NR (1992) Self-administration of psychomotor stimulants using progressive ratio schedules of reinforcement. In: Boulton AA, Baker GB, Wu PH, editors. Animal models of drug addiction. New York, NY: Humana Press. 233-269.
44. Cohen J (1988) Statistical power analysis for the behavioral sciences. Hillsdale, NJ: L. Erlbaum Associates.
45. Farid WO, McCallum D, Tait RJ, Dunlop SA, Hulse GK, (2009) Minor pathological changes are induced by naltrexone-poly(DL-lactide) implants in pregnant rats. J Biomed Mater Res A 91: 964-974.
46. Narita M, Miyagawa K, Mizuo K, Yoshida T, Suzuki T, (2006) Prenatal and neonatal exposure to low-dose of bisphenol-A enhance the morphine-induced hyperlocomotion and rewarding effect. Neurosci Lett 402: 249-252.
47. Rocha BA, Mead AN, Kosofsky BE, (2002) Increased vulnerability to self-administer cocaine in mice prenatally exposed to cocaine. Psychopharmacology (Berl) 163: 221-229.
48. Spano MS, Ellgren M, Wang X, Hurd YL, (2007) Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol Psychiatry 61: 554-563.
49. Riley MA, Vathy I, (2006) Mid- to late gestational morphine exposure does not alter the rewarding properties of morphine in adult male rats. Neuropharmacology 51: 295-304.
50. Arnold JM, Roberts DC, (1997) A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 57: 441-447.
51. Vanderschuren LJ, Kalivas PW, (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 151: 99-120.
52. White FJ, Kalivas PW, (1998) Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 51: 141-153.
53. Wassum KM, Cely IC, Maidment NT, Balleine BW, (2009) Disruption of endogenous opioid activity during instrumental learning enhances habit acquisition. Neuroscience 163: 770-780.
54. Chen F, Lawrence AJ, (2000) Effect of chronic ethanol and withdrawal on the mu-opioid receptor- and 5-Hydroxytryptamine(1A) receptor-stimulated binding of [(35)S]Guanosine-5′-O-(3-thio)triphosphate in the fawn-hooded rat brain: A quantitative autoradiography study. J Pharmacol Exp Ther 293: 159-165.
55. Chen F, Lawrence AJ, (2004) Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G Proteins in the amygdala of fawn-hooded rats. J Pharmacol Exp Ther 310: 1020-1026.
56. Bickel WK, Marsch LA, Carroll ME, (2000) Deconstructing relative reinforcing efficacy and situating the measures of pharmacological reinforcement with behavioral economics: a theoretical proposal. Psychopharmacology (Berl) 153: 44-56.
57. Shabat-Simon M, Levy D, Amir A, Rehavi M, Zangen A, (2008) Dissociation between rewarding and psychomotor effects of opiates: differential roles for glutamate receptors within anterior and posterior portions of the ventral tegmental area. J Neurosci 28: 8406-8416.
58. Meyerson BJ, Berg M, Johansson B, (1988) Neonatal naltrexone treatment: effects on sexual and exploratory behavior in male and female rats. Pharmacol Biochem Behav 31: 63-67.
59. Paul L, Diaz J, Bailey B, (1978) Behavioral effects of chronic narcotic antagonist administration of infant rats. Neuropharmacology 17: 655-657.
60. Willig F, Palacios A, Monmaur P, M'Harzi M, Laurent J, et al. (1987) Short-term memory, exploration and locomotor activity in aged rats. Neurobiol Aging 8: 393-402.
61. Klemenhagen KC, Gordon JA, David DJ, Hen R, Gross CT, (2006) Increased fear response to contextual cues in mice lacking the 5-HT1A receptor. Neuropsychopharmacology 31: 101-111.
62. Babbini M, Davis WM, (1972) Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment. Br J Pharmacol 46: 213-224.
63. Kalinichev M, Easterling KW, Holtzman SG, (2003) Long-lasting changes in morphine-induced locomotor sensitization and tolerance in Long-Evans mother rats as a result of periodic postpartum separation from the litter: a novel model of increased vulnerability to drug abuse? Neuropsychopharmacology 28: 317-328.
64. Koob GF, Bloom FE, (1988) Cellular and molecular mechanisms of drug dependence. Science 242: 715-723.
65. Lett BT, (1989) Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine. Psychopharmacology (Berl) 98: 357-362.
66. Kalinichev M, Easterling KW, Holtzman SG, (2002) Early neonatal experience of Long-Evans rats results in long-lasting changes in reactivity to a novel environment and morphine-induced sensitization and tolerance. Neuropsychopharmacology 27: 518-533.
67. Kalinichev M, White DA, Holtzman SG, (2004) Individual differences in locomotor reactivity to a novel environment and sensitivity to opioid drugs in the rat. I. Expression of morphine-induced locomotor sensitization. Psychopharmacology (Berl) 177: 61-67.
68. Olive MF, Maidment NT, (1998) Opioid regulation of pallidal enkephalin release: bimodal effects of locally administered mu and delta opioid agonists in freely moving rats. J Pharmacol Exp Ther 285: 1310-1316.
69. Tempel A, Espinoza K, (1992) Morphine-induced downregulation of mu-opioid receptors and peptide synthesis in neonatal rat brain. Ann N Y Acad Sci 654: 529-530.
70. Yoburn BC, Goodman RR, Cohen AH, Pasternak GW, Inturrisi CE, (1985) Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment. Life Sci 36: 2325-2332.
71. Yoburn BC, Luke MC, Pasternak GW, Inturrisi CE, (1988) Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE. Life Sci 43: 1319-1324.
72. Lesscher HM, Bailey A, Burbach JP, Van Ree JM, Kitchen I, et al. (2003) Receptor-selective changes in mu-, delta- and kappa-opioid receptors after chronic naltrexone treatment in mice. Eur J Neurosci 17: 1006-1012.
73. Lee SC, Yoburn BC, (2000) The effect of nimodipine on opioid antagonist-induced upregulation and supersensitivity. Pharmacol Biochem Behav 66: 347-351.
74. Grota LJ, (1973) Effects of litter size, age of young, and parity on foster mother behaviour in Rattus norvegicus. Anim Behav 21: 78-82.
75. Nowosielski-Slepowron BJ, Park AW, (1974) The criteria of litter size in relation to growth of the rat. I. The influence of numbers. Acta Morphol Neerl Scand 12: 299-316.
76. D'Amato FR, Castellano C, Ammassari-Teule M, Oliverio A, (1988) Prenatal antagonism of stress by naltrexone administration: early and long-lasting effects on emotional behaviors in mice. Dev Psychobiol 21: 283-292.
77. Zagon IS, McLaughlin PJ, (1984) Naltrexone modulates body and brain development in rats: a role for endogenous opioid systems in growth. Life Sci 35: 2057-2064.
78. Zagon IS, McLaughlin PJ, (1985) Opioid antagonist-induced regulation of organ development. Physiol Behav 34: 507-511.
79. Hauser KF, McLaughlin PJ, Zagon IS, (1989) Endogenous opioid systems and the regulation of dendritic growth and spine formation. J Comp Neurol 281: 13-22.
80. Zagon IS, McLaughlin PJ, (1983) Naltrexone modulates growth in infant rats. Life Sci 33: 2449-2454.
81. Zagon IS, McLaughlin PJ, (1986) Opioid antagonist-induced modulation of cerebral and hippocampal development: histological and morphometric studies. Brain Res 393: 233-246.
82. Zagon IS, McLaughlin PJ, (1987) Endogenous opioid systems regulate cell proliferation in the developing rat brain. Brain Res 412: 68-72.
83. Hulse G, O'Neil G, (2002) Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol 42: 569-573.
84. Zagon IS, Hurst WJ, McLaughlin PJ, (1997) Transplacental transfer of naltrexone in rats. Life Sci 61: 1261-1267.
85. Zagon IS, Hurst WJ, McLaughlin PJ, (1998) Naltrexone is not detected in preweaning rats following transplacental exposure: implications for growth modulation. Life Sci 62: 221-228.
86. Bhargava HN, Rahmani NH, Villar VM, Larsen AK, (1993) Effects of naltrexone on pharmacodynamics and pharmacokinetics of intravenously administered morphine in the rat. Pharmacology 46: 66-74.
87. Wang HY, Frankfurt M, Burns LH, (2008) High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence. PLoS One 3: e1554.
88. Ludden TM, Malspeis L, Baggot JD, Sokoloski TD, Frank SG, et al. (1976) Tritiated naltrexone binding in plasma from several species and tissue distribution in mice. J Pharm Sci 65: 712-716.
89. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC, (1984) Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 45: 15-19.
90. Wall ME, Brine DR, Perez-Reyes M, (1981) Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 9: 369-375.
91. Bertolotti M, Ferrari A, Vitale G, Stefani M, Trenti T, et al. (1997) Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J Hepatol 27: 505-511.
92. Wall ME, Perez-Reyes M, Brine DR, Cook CE, (1984) Naltrexone disposition in man after subcutaneous administration. Drug Metab Dispos 12: 677-682.
93. Misra AL, Bloch R, Vardy J, Mule SJ, Verebely K, (1976) Disposition of (15,16-3H)naltrexone in the central nervous system of the rat. Drug Metab Dispos 4: 276-280.
94. Yoburn BC, Cohen AH, Inturrisi CE, (1986) Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. J Pharmacol Exp Ther 237: 126-130.
95. Darlington RB, Dunlop SA, Finlay BL, (1999) Neural development in metatherian and eutherian mammals: variation and constraint. J Comp Neurol 411: 359-368.
96. Robinson SR, Dreher B, (1990) The visual pathways of eutherian mammals and marsupials develop according to a common timetable. Brain Behav Evol 36: 177-195.
97. Finlay BL, Darlington RB, (1995) Linked regularities in the development and evolution of mammalian brains. Science 268: 1578-1584.
98. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson RC, (2004) Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants. Addict Biol 9: 67-72.
99. O'Brien CP, Gastfriend DR, Forman RF, Schweizer E, Pettinati HM, (2011) Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone. Am J Addict 20: 106-112.
100. Dannon PN, Lowengrub K, Musin E, Gonopolski Y, Kotler M, (2005) Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol 25: 593-596.
101. Kim SW, (1998) Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry 59: 159-164.
102. Kim SW, Grant JE, Adson DE, Shin YC, (2001) Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49: 914-921.
103. Lahti T, Halme JT, Pankakoski M, Sinclair D, Alho H, (2010) Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacol Bull 43: 35-44.
104. Agrawal YP, (2005) Low dose naltrexone therapy in multiple sclerosis. Med Hypotheses 64: 721-724.
105. Cree BA, Kornyeyeva E, Goodin DS, (2010) Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 68: 145-150.
106. Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, et al. (2008) A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 14: 1076-1083.
107. Lee MW, Fujioka K, (2009) Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother 10: 1841-1845.
108. Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, et al. (2009) Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 10: 1069-1081.
109. Witkamp RF, (2011) Current and future drug targets in weight management. Pharm Res 28: 1792-1818.
110. Jacobson B, Nyberg K, Gronbladh L, Eklund G, Bygdeman M, et al. (1990) Opiate addiction in adult offspring through possible imprinting after obstetric treatment. BMJ 301: 1067-1070.
111. Nyberg K, Allebeck P, Eklund G, Jacobson B, (1992) Socio-economic versus obstetric risk factors for drug addiction in offspring. Br J Addict 87: 1669-1676.
112. Nyberg K, Buka SL, Lipsitt LP, (2000) Perinatal medication as a potential risk factor for adult drug abuse in a North American cohort. Epidemiology 11: 715-716.